Bicara Therapeutics Inc. (BCAX): Total Assets
$430.99M
As of 2025-12-31
$512.24M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $430.99M | -15.5% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $510.00M | +118.0% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $233.98M | n/a | 2025-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Bicara Therapeutics Inc. (BCAX) | 2025-12-31 | $430.99M | -15.5% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $432.97M | +24.1% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $433.81M | +718.5% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $424.43M | -11.2% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $418.43M | +54.1% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $448.38M | +172.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $451.45M | -26.6% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $408.89M | +49.2% |
Compare BCAX, ARQT, BGM, MLTX side by side · Screen every company in Pharmaceutical Preparations ↗